niftify.in

Business Standard

Orchid AMS eyes Rs 300 cr turnover in 3 years for antimicrobial resistance

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official. Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs). Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI. "This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,

Business Standard

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Orchid Pharma said that it has partnered with Cipla to ensure widespread and rapid distribution of the company's new drug- Cefepime-Enmetazobactam across India.

Business Line

Orchid Pharma ties up with Cipla for new UTI drug’s distribution

It is estimated that the drug sales could reach an annual value of about ₹100 crore, in about 2-3 years

Business Standard

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.

Business Standard

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence